Your browser doesn't support javascript.
loading
Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohort.
Grabar, Sophie; Potard, Valérie; Piroth, Lionel; Abgrall, Sophie; Bernard, Louis; Allavena, Clotilde; Caby, Fabienne; de Truchis, Pierre; Duvivier, Claudine; Enel, Patricia; Katlama, Christine; Khuong, Marie-Aude; Launay, Odile; Matheron, Sophie; Melica, Giovanna; Melliez, Hugues; Meynard, Jean-Luc; Pavie, Juliette; Slama, Laurence; Bregigeon, Sylvie; Tattevin, Pierre; Capeau, Jacqueline; Costagliola, Dominique.
Afiliación
  • Grabar S; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital St Antoine, F75012, Paris, France.
  • Potard V; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F75013, Paris, France.
  • Piroth L; Infectious Diseases Department, CHU Dijon, and Inserm CIC 1432 Université de Bourgogne, Dijon, France.
  • Abgrall S; AP-HP, Hôpital Béclère, Service de Médecine Interne, Clamart, and Université Paris-Saclay, CESP INSERM U1018, Le Kremlin-Bicêtre, France.
  • Bernard L; Université de Tours, Tours, France.
  • Allavena C; Infectious Diseases Department, INSERM EA1413, CHU de Nantes, Nantes, France.
  • Caby F; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F75013, Paris, France.
  • de Truchis P; Unité VIH-IST, Service d'Immuno-Hematologie, Hôpital Victor Dupouy, Argenteuil, France.
  • Duvivier C; AP-HP Hôpital Raymond Poincaré, Université Paris-Saclay, Garches, France.
  • Enel P; AP-HP, Hôpital Necker-Enfants Malades, Service de Maladies Infectieuses et Tropicales, Centre d'Infectiologie Necker-Pasteur, Paris, France.
  • Katlama C; IHU Imagine, Paris, France.
  • Khuong MA; Institut Cochin-CNRS 8104-INSERM U1016, Université Paris Cité, Paris, France.
  • Launay O; Institut Pasteur, Centre Médical de l'Institut Pasteur, Paris, France.
  • Matheron S; Assistance Publique-Hôpitaux de Marseille, Public Health Department, Marseille, and Aix-Marseille University, CEReSS, Health Service Research and Quality of Life Center, Marseille, France.
  • Melica G; AP-HP, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
  • Melliez H; Hôpital Delafontaine, Saint-Denis, France.
  • Meynard JL; Université Paris-Cité, AP-HP, Hôpital Cochin, INSERM, CIC 1417, Paris, France.
  • Pavie J; Service de Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, GHU Paris Nord, AP-HP, Paris, France.
  • Slama L; Clinical Immunology and Infectious Diseases Department, Henri Mondor Hospital, Creteil, France.
  • Bregigeon S; Médecine Interne, Hôpital Riaumont, 62 800, Liévin, France.
  • Tattevin P; AP-HP, Department of Infectious Diseases, Saint-Antoine Hospital, Paris, France.
  • Capeau J; Department of Immunology and Infectious Diseases, AP-HP Hôtel-Dieu, Paris, France.
  • Costagliola D; Infectious Diseases Unit, Hôtel Dieu Hospital, APHP, Paris, France.
J Antimicrob Chemother ; 78(3): 757-768, 2023 03 02.
Article en En | MEDLINE | ID: mdl-36683307
BACKGROUND: Many studies have reported weight gain in ART-naive people living with HIV (PWH) initiating an integrase strand-transfer inhibitor-based regimen. We studied the impact of early or advanced presentation and that of individual drugs in PWH initiating combined ART (cART) between 2012 and 2018. METHODS: From the French Hospital Database HIV cohort, we assessed factors associated with a weight gain  ≥10%, weight change after cART initiation or BMI increase  ≥5 kg/m2 up to 30 months. The analyses were conducted overall, and among PWH with early (primary infection or CD4 >350/mm3 and viral load  <100 000 copies/mL, without AIDS) and advanced presentation (AIDS or CD4 <200/mm3, not during primary infection). RESULTS: At 30 months, 34.5% (95% CI: 33.5-35.6) of the 12 773 PWH had a weight gain ≥10%, with 20.9% (95% CI: 19.6-22.2) among the 5794 with early presentation and 63.1% (95% CI: 60.9-65.3) among the 3106 with advanced presentation. Weight gain was 2.8 kg (95% CI: 2.0-3.7) for those with early presentation and 9.7 kg (95% CI: 8.4-11.1) for those with advanced presentation. Most weight gain occurred in the first 12 months. Underweight and obese PWH were at significantly higher risk of a BMI increase  ≥5 kg/m2 than normal-weight PWH. Results differed within classes and by outcome. Raltegravir and dolutegravir were consistently associated with greater weight gain than the other third agents. Tenofovir alafenamide was also associated with higher weight gain than tenofovir disoproxil or abacavir. CONCLUSIONS: After initiating cART, PWH with early presentation exhibited a small weight gain, whereas it was large among those with advanced presentation. The choice of ART should account for the risk of weight gain, especially for PWH who present with advanced disease and/or are obese.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH / Síndrome de Inmunodeficiencia Adquirida / Fármacos Anti-VIH Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: J Antimicrob Chemother Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH / Síndrome de Inmunodeficiencia Adquirida / Fármacos Anti-VIH Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: J Antimicrob Chemother Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido